鼻拭子PCR指导ICU疑似社区获得性肺炎的经验性万古霉素降阶梯治疗
STOP-Vanc 是一项单中心、实用性、前瞻性、非盲随机对照试验，纳入 277 例疑似社区获得性肺炎（CAP）的成人 ICU 患者，按 1:1 随机分为两组：在常规治疗基础上加做 MRSA 鼻拭子 PCR 指导万古霉素降阶梯治疗，或仅接受常规治疗。干预组 MRSA PCR 阴性预测值为 98.9%，但主要终点无万古霉素存活小时数两组无显著差异，即未减少万古霉素使用时长或 30 天死亡率。
要点
- MRSA 鼻拭子 PCR 在 ICU 疑似 CAP 人群中阴性预测值达 98.9%。
- 仅提供 PCR 检测结果不足以减少经验性万古霉素使用，可能需配合抗菌药物管理干预。
核心结论
- 在 ICU 疑似 CAP 患者中，MRSA 鼻拭子 PCR 虽阴性预测值高，但未减少万古霉素使用时长或 30 天死亡率。
研究设计与样本
- 实用性、前瞻性、单中心、非盲随机对照试验，277 例疑似 CAP 的成人 ICU 患者按 1:1 随机分组。
- 干预组在常规治疗基础上加做 MRSA 鼻拭子 PCR 检测，对照组仅接受常规治疗。
主要发现
- 干预组 MRSA PCR 鼻拭子检测阴性预测值为 98.9%。
- 研究结论指出 MRSA PCR 鼻拭子检测未减少万古霉素使用时长或 30 天死亡率。
临床怎么用
- 不宜仅凭 MRSA 鼻拭子 PCR 结果即期待经验性万古霉素自动降阶梯，需配合临床医生教育与抗菌药物管理干预。
局限性
- 单中心、非盲设计，结论外推需谨慎。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
Clin Infect Dis. 2026 Sep 2;83(2):e260-e269. doi: 10.1093/cid/ciag295. ABSTRACT BACKGROUND: Fear of methicillin-resistant Staphylococcus aureus (MRSA) as a cause of community-acquired pneumonia (CAP) frequently leads to empiric vancomycin coverage. Data evaluating the use of MRSA polymerase chain reaction (PCR) nasal swab testing to guide vancomycin de-escalation is limited for patients in the intensive care unit (ICU). METHODS: Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin (STOP-Vanc) is a pragmatic, prospective, single-center, non-blinded randomized trial in which adult ICU patients with suspicion of CAP were randomized 1:1 to receive usual care either with (intervention) or without (control) the addition of MRSA nares PCR testing following ICU admission. The primary outcome was vancomycin-free hours alive, defined as the expected number of hours alive and free of vancomycin use within the first 7 days of trial enrollment as estimated using a longitudinal proportional odds state transition model adjusted for baseline covariates. RESULTS: A total of 277 adult ICU patients were randomized. Methicillin-resistant Staphylococcus aureus PCR nasal swab testing had a negative predictive value (NPV) of 98.9% in the intervention arm. The primary endpoint, vancomycin-free hours alive, was 105.7 in the control arm and 109.7 in the intervention arm (adjusted difference, 4 hours; 95% CI, -9.5-18.2; P = .458). CONCLUSIONS: Despite MRSA PCR nasal swab testing demonstrating a high NPV in this critically ill population, MRSA PCR nasal swab testing did not decrease the duration of vancomycin use or 30-day mortality among ICU patients with suspected CAP. Additional clinician education and antimicrobial stewardship interventions might be needed to reduce vancomycin use in this patient population. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov NCT06272994 (STOP-Vanc). PMID: 42227019 | PMC: PMC13537149 | DOI: 10.1093/cid/ciag295
引用
- PubMed 高证据 · 肺炎：Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin: A Randomized Controlled Trial
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。